Stockreport

NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) [Seeking Alpha]

NervGen Pharma Corp. - Common stock  (NGEN) 
PDF NGEN's regulatory engagement is strong, with expedited FDA pathways under discussion and a Phase 3 trial for up to 150 patients set to begin this summer. Recent $10M [Read more]